Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

This study tests belzutifan — a pill that blocks a protein involved in tumor growth — in women with a rare form of gynecologic cancer called clear cell carcinoma that has come back after prior treatment. This cancer type can affect the ovaries, uterus, cervix, or other gynecologic organs. **You may be eligible if...** - You have confirmed recurrent or persistent clear cell carcinoma of the ovary or other gynecologic origin - Your cancer has returned or progressed after at least one prior treatment - Your overall health is adequate for treatment (good performance status) - You have measurable disease on imaging **You may NOT be eligible if...** - You have never been treated for this cancer before - You have active brain metastases (cancer spread to the brain) - You have severe anemia or other blood disorders that haven't been treated - You are pregnant or breastfeeding - You are on medications that strongly interact with belzutifan Talk to your doctor to see if this trial is right for you.